Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 16, 2016 - Issue 1
Submit an article Journal homepage
282
Views
5
CrossRef citations to date
0
Altmetric
Reviews

Cost of arthritis: a systematic review of methodologies used for direct costs

TKT LoResearch Centre for Gender, Health and Ageing, The University of Newcastle, Callaghan, AustraliaCorrespondence[email protected]
,
Lynne ParkinsonCentral Queensland University, School of Human Health and Social Sciences, Rockhampton, Australia
,
Michelle CunichFaculty of Pharmacy, Charles Perkins Centre, The University of Sydney, Camperdown, Australia;School of Medicine and Public Health, Faculty of Health and Medicine, The University of Newcastle, Callaghan, Australia
&
Julie BylesResearch Centre for Gender, Health and Ageing, The University of Newcastle, Callaghan, Australia
Pages 51-65 | Published online: 22 Dec 2015

References

  • Papers of special note have been highlighted as:
  • • of interest
  • Australian Institute of Health and Welfare (AIHW). A snapshot of arthritis in Australia 2010. Arthritis series no. 13. Cat. no. PHE 126. Canberra: AIHW; 2010.
  • Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the global burden of disease study 2013. The Lancet. 2015;386(9995):743–800.
  • Australian Institute of Health and Welfare (AIHW). Impairments and disability associated with arthritis and osteoporosis. Arthritis series no. 4. Cat. no. PHE 90. Canberra: AIHW; 2007.
  • Australian Institute of Health and Welfare (AIHW). National indicators for monitoring osteoarthritis, rheumatoid arthritis, and osteoporosis. Arthritis series no. 2. Cat. no. PHE 77. Canberra: AIHW; 2006.
  • Australian Institute of Health and Welfare (AIHW). Use of health services for arthritis and osteoporosis. Arthritis series no. 14 Cat. no. PHE 130. Canberra: AIHW; 2010.
  • Lo TKT, Parkinson L, Cunich M, et al. A 6-year trend of the healthcare costs of arthritis in a population-based cohort of older women. Exp Rev Pharmacoecon Outcomes Res., 1–9, 2015.
  • Australian Institute of Health and Welfare (AIHW). Arthritis and osteoporosis in Australia 2008. Arthritis series no. 8. Cat. no. PHE 106. Canberra: AIHW; 2008.
  • Clarke AE, Zowall H, Levinton C, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol. 1997;24(6):1051–1060.
  • Gabriel SE, Crowson CS, Campion ME, et al. Direct medical costs unique to people with arthritis. J Rheumatol. 1997;24(4):719–725.
  • Lanes SF, Lanza LL, Radensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum. 1997;40(8):1475–1481.
  • Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. Value Health. 2001;4(4):329–334.
  • Van Jaarsveld CH, Jacobs JW, Schrijvers AJ, et al. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol. 1998;37(8):837–847.
  • Waddell D, Rein A, Panarites C, et al. Cost implications of introducing an alternative treatment for patients with osteoarthritis of the knee in a managed care setting. Am J Manag Care. 2001;7(10):981–991.
  • March L, Cross M, Tribe K, et al. Cost of joint replacement surgery for osteoarthritis: the patients’ perspective. J Rheumatol. 2002;29(5):1006–1014.
  • Le Pen C, Reygrobellet C, Gerentes I. Financial cost of osteoarthritis in France. The “COART” France study. Joint Bone Spine. 2005;72(6):567–570.
  • Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006;65(9):1175–1183.
  • Osborne RH, Nikpour M, Busija L, et al. Prevalence and cost of musculoskeletal disorders: a population-based, public hospital system healthcare consumption approach. J Rheumatol. 2007;34(12):2466–2475.
  • Chermont GC, Kowalski SC, Ciconelli RM, et al. Resource utilization and the cost of rheumatoid arthritis in Brazil. Clin Exp Rheumatol. 2008;26(1):24–31.
  • Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics. 2005;23(3):243–257.
  • Akobundu E, Ju J, Blatt L, et al. Cost-of-illness studies: a review of current methods. Pharmacoeconomics. 2006;24(9):869–890.
  • Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1 −34.
  • Ganann R, Ciliska D, Thomas H. Expediting systematic reviews: methods and implications of rapid reviews. Implementation Sci. 2010;5(1):56.
  • Hopewell S, Clarke MJ, Lefebvre C, et al. Handsearching versus electronic searching to identify reports of randomized trials. Cochrane Database Syst Rev.2007;(2), MR000001. DOI: 10.1002/14651858.MR000001.pub2
  • Pagano E, Brunetti M, Tediosi F, et al. Costs of diabetes. A methodological analysis of the literature. Pharmacoeconomics. 1999;15(6):583–595.
  • Merkesdal S, Ruof J, Huelsemann JL, et al. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J Rheumatol. 2001;28(3):657–661.
  • Jin H, McCrone P. Cost-of-illness studies for bipolar disorder: systematic review of international studies. Pharmacoeconomics. 2015;33(4):341–353.
  • Becker C. Cost-of-illness studies of atrial fibrillation: methodological considerations. Expert Rev Pharmacoecon Outcomes Res. 2014;14(5):661–684.
  • Ó Céilleachair AJ, Hanly P, Skally M, et al. Cost comparisons and methodological heterogeneity in cost-of- illness studies: the example of colorectal cancer. Med Care. 2013;51(4):339–350.
  • Yabroff KR, Borowski L, Lipscomb J. Economic studies in colorectal cancer: challenges in measuring and comparing costs. JNCI Monographs. 2013;(2013)(46):62–78.
  • Catay E, Del Cid CC, Narvaez L, et al. Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era. ClinicoEconomics and Outcomes Research. 2012;4(1):219–225.
  • Kawatkar AA, Jacobsen SJ, Levy GD, et al. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res (Hoboken). 2012;64(11):1649–1656.
  • Kvamme MK, Lie E, Kvien TK, et al. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry. Rheumatology (Oxford). 2012;51(9):1618–1627.
  • Rafia R, Ara R, Packham J, et al. Healthcare costs and productivity losses directly attributable to ankylosing spondylitis. Clin Exp Rheumatol. 2012;30(2):246–253.

• Reports the economic burden of spondyloarthritis.

  • Tarride JE, Haq M, O’Reilly DJ, et al The excess burden of osteoarthritis in the province of Ontario, Canada. Arthritis Rheum. 2012;64(4):1153–1161.
  • Van Den Akker-Van Marle EM, Chorus AMJ, Vliet Vlieland TPM, et al. Cost of rheumatic disorders in the Netherlands. Best Pract Research: Clin Rheumatol. 2012;26(5):721–731.
  • Wu EQ, Forsythe A, Guerin A, et al. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther. 2012;19(6):e157–e166.
  • Zhu TY, Tam L-S, Li EK. Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of- illness study. Rheumatology (Oxford). 2011;50(7):1293–1301.
  • Access Economics Pty Limited. The economic cost of arthritis in New Zealand in 2010. New Zealand: Arthritis; 2010.
  • Della Rossa A, Neri R, Talarico R, et al. Diagnosis and referral of rheumatoid arthritis by primary care physician: results of a pilot study on the city of Pisa, Italy. Clinical Rheumatology. 2010;29(1):71–81.
  • Poole CD, Lebmeier M, Ara R, et al. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK. Rheumatology (Oxford). 2010;49(10):1949–1956.

• Reports the healthcare cost of psoriatic arthritis and the factors associated with higher cost.

  • Strombeck B, Englund M, Bremander A, et al. Cost of illness from the public payers’ perspective in patients with ankylosing spondylitis in rheumatological care. J Rheumatol. 2010;37(11):2348–2355.
  • Torres TM, Ferraz MB, Ciconelli RM. Resource utilisation and cost of ankylosing spondylitis in Brazil. Clin Exp Rheumatol. 2010;28(4):490–497.
  • Flipon E, Brazier M, Clavel G, et al. Is it possible to identify early predictors of the future cost of chronic arthritis? The VErA project. Fundam Clin Pharmacol. 2009;23(1):105–113.

• Provides information about the direct and indirect cost of rheumatoid arthritis and about the factors associated with higher cost.

  • Kleinman N, Harnett J, Melkonian A, et al. Burden of fibromyalgia and comparisons with osteoarthritis in the workforce. J Occup Environ Med. 2009;51(12):1384–1393.
  • Loza E, Lopez-Gomez JM, Abasolo L, et al. Economic burden of knee and hip osteoarthritis in Spain. Arthritis Rheum. 2009;61(2):158–165.

• Provides information about the direct and indirect cost of rheumatoid arthritis and about the factors associated with higher cost.

  • Ollendorf DA, Klingman D, Hazard E, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther. 2009;31(4):825–835.

• Provides information about usage of tumor necrosis factor inhibitors among rheumatoid arthritis patients.

  • Silverman S, Dukes EM, Johnston SS, et al. The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Curr Med Res Opin. 2009;25(4):829–840.
  • Kobelt G, Woronoff A-S, Richard B, et al. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine. 2008;75(4):408–415.
  • White AG, Birnbaum HG, Janagap C, et al. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States. J Occup Environ Med. 2008;50(9):998–1005.
  • White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med. 2008;50(1):13–24.

• Reports the economic burden of fibromyalgia and compares that of osteoarthritis.

  • Wu EQ, Patel PA, Ap Y, et al Disease-related and all-cause health care costs of elderly patients with gout. J Manage Care Pharm. 2008;14(2):164–175.
  • Zhu TY, Tam LS, Lee VWY, et al Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatology (Oxford). 2008;47(9):1422–1425.
  • Puig-Junoy J, Ruiz Zamora A. Socio-economic costs of osteoarthritis: A systematic review of cost-of-illness studies. Semin Arthritis Rheum. 2015;44(5):531–541.
  • Australian Institute of Health and Welfare (AIHW). Health expenditure for arthritis and musculoskeletal conditions. Arthritis series no. 10. Cat. no. PHE 115. Canberra: AIHW, 2009.
  • Collins CE, Patterson A, Fitzgerald D. Higher diet quality does not predict lower Medicare costs but does predict number of claims in mid-aged Australian women. Nutrients. 2011;3(1):40–48.
  • Tooth LR, Hockey R, Treloar S, et al. Does government subsidy for costs of medical and pharmaceutical services result in higher service utilization by older widowed women in Australia?. BMC Health Serv Res. 2012;12:179.
  • Colagiuri S, Lee CMY, Colagiuri R, et al. The cost of overweight and obesity in Australia. Med J Aust. 2010;192(5):260–264.
  • Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health-System Pharm. 2006;63(24):2451–2465.
  • Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum. 2002;32(3 Suppl 1):25–32.
  • Steen KSS, Nurmohamed MT, Visman I, et al. Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):256–259.
  • Sheehy C, Murphy E, Barry M. Depression in rheumatoid arthritis: underscoring the problem. Rheumatology (Oxford). 2006;45(11):1325–1327.
  • Mohan AK, Cote TR, Siegel JN, et al. Infectious complications of biologic treatments of rheumatoid arthritis. Curr Opin Rheumatol. 2003;15(3):179–184.
  • Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005;24(3):465–488.
  • Institute for Digital Research and Education (IDRE). Regression Diagnostics (UCLA, 2015). [updated 2015 June 4]. Available from: http://www.ats.ucla.edu/stat/stata/webbooks/reg/chapter2/statareg2.htm
  • Stoltzfus JC, Nishijima D, Melnikow J. Why quantile regression makes good sense for analyzing economic outcomes in medical research. Acad Emerg Med. 2012;19(7):850–851.
  • Barnabe C, Thanh NX, Ohinmaa A, et al Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission. Ann Rheum Dis. 2013;72(10):1664–1668.
  • Cheng LI, Rascati KL. Impact of Medicare part D for Medicare-age adults with arthritis: Prescription use, prescription expenditures, and medical spending from 2005 to 2008. Arthritis Care Res (Hoboken). 2012;64(9):1423–1429.
  • Lurie IZ, Dunlop DD, Manheim LM. Trends in out-of-pocket medical care expenditures for Medicare-age adults with arthritis between 1998 and 2004. Arthritis Rheum. 2008;58(8):2236–2240.
  • Lo TKT, Parkinson L, Cunich M, et al. Factors associated with higher healthcare costs in individuals living with arthritis: evidence from the quantile regression approach. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):833–841.
  • Jacobsson LTH, Lindroth Y, Marsal L, et al. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand J Rheumatol. 2007;36(3):179–183.
  • Kirchhoff T, Ruof J, Mittendorf T, et al. Cost of illness in rheumatoid arthritis in Germany in 1997 −98 and 2002: cost drivers and cost savings. Rheumatology (Oxford). 2011;50(4):756–761.
  • Australian Institute of Health and Welfare (AIHW). Data sources for monitoring arthritis and other musculoskeletal conditions. Arthritis series no.19. Cat no. PHE 175. Canberra: AIHW; 2014.
  • Byles JE, Dobson A. Australian longitudinal study on women’s health. The value of time in longitudinal studies of ageing. Lessons from the Australian longitudinal study on women’s health. Australas J Ageing. 2011;30(Suppl 2):6–12.
  • Women’s Health Australia. Australian Longitudinal Study on Women’s Health: Study overview. 2015. updated 2015 June 4 Available from: http://www.alswh.org.au/
  • Wrigley N. Unobserved heterogeneity and the analysis of longitudinal spatial choice data. European Journal of Population/Revue Européenne De Démographie. 1990;6(4):327–358.
  • Wagstaff A. Estimating health insurance impacts under unobserved heterogeneity: the case of Vietnam’s health care fund for the poor. Health Econ. 2010;19(2):189–208.
  • Coakley J, Fuertes A-M, Smith R. Unobserved heterogeneity in panel time series models. Comput Stat Data Anal. 2006;50(9):2361–2380.
  • Abrevaya J, Dahl CM. The effects of birth inputs on birthweight: evidence from quantile estimation on panel data. J Business Econ Stat. 2008;26(4):379–397.
  • Bache S, Dahl C, Kristensen J. Headlights on tobacco road to low birthweight outcomes. Empir Econ. 2013;44(3):1593–1633.
  • Koenker R. Quantile regression for longitudinal data. J Multivar Anal. 2004;91(1):74–89.
  • Moran JL, Solomon PJ, Peisach AR, et al. New models for old questions: generalized linear models for cost prediction. J Eval Clin Pract. 2007;13(3):381–389.
  • Austin PC, Tu JV, Daly PA, et al. The use of quantile regression in health care research: A case study examining gender differences in the timeliness of thrombolytic therapy. Stat Med. 2005;24(5):791–816.
  • Xie F. The need for standardization: a literature review of indirect costs of rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 2008;59(7):1027–1033.
  • Furneri G, Mantovani LG, Belisari A, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(4 SUPPL.73):S72- S84.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.